Investigating Vernal Pool Fairy Shrimp Exposure to Organophosphate Pesticides: Implications for Population-Level Risk Assessment.

Vernal pool fairy shrimp, Branchinecta lynchi, is a freshwater crustacean endemic to California and Oregon, including California's Central Valley. B. lynchi is listed as a Federally Threatened species under the US Endangered Species Act, and as a vulnerable species on the IUCN Red List. Threats that may negatively impact vernal pool fairy shrimp populations include pesticide applications to agricultural land use (e.g., agrochemicals such as organophosphate pesticides) and climate changes that impact vernal pool hydrology. Pop-GUIDE (Population model Guidance, Use, Interpretation, and Development for Ecological risk assessment) is a comprehensive tool that facilitates development and implementation of population models for ecological risk assessment and can be used to document the model derivation process. We employed Pop-GUIDE to document and facilitate the development of a population model for investigating impacts of organophosphate pesticides on vernal pool fairy shrimp populations in California's Central Valley. The resulting model could be applied in combination with field assessment and laboratory-based chemical analysis to link effects from pesticide exposure to adverse outcomes in populations across their range. B. lynchi has a unique intra-annual life cycle that is largely dependent upon environmental conditions. Future deployment of this population model should include complex scenarios consisting of multiple stressors, whereby the model is used to examine scenarios that combine chemical stress resulting from exposure to pesticides and climate changes.

Assessment of status of white sucker (Catostomus commersoni) populations exposed to bleached kraft pulp mill effluent.

Credible ecological risk assessments often need to include analysis of population-level impacts. In the present study, a predictive model was developed to investigate population dynamics for white sucker (Catostomus commersoni) exposed to pulp mill effluent at a well-studied site in Jackfish Bay, Lake Superior, Canada. The model uniquely combines a Leslie population projection matrix and the logistic equation to translate changes in the fecundity and the age structure of a breeding population of white sucker exposed to pulp mill effluent to alterations in population growth rate. Application of this density-dependent population projection model requires construction of a life table for the organism of interest, a measure of carrying capacity, and an estimation of the effect of stressors on vital rates. A white sucker population existing at carrying capacity and subsequently exposed to pulp mill effluent equivalent to a documented exposure experienced during the period 1988 to 1994 in Jackfish Bay would be expected to exhibit a 34% to 51% annual decrease in recruitment during the first 5 yr of exposure and approach a population size of 71% of carrying capacity. The Jackfish Bay study site contains monitoring data for biochemical endpoints in white sucker, including circulating sex steroid concentrations, that could be combined with population modeling to utilize the model demonstrated at the Jackfish Bay study site for investigation of other white sucker populations at sites that are less data-rich.

Assessment of disease activity in multiple sclerosis phenotypes with combined gadolinium- and superparamagnetic iron oxide-enhanced MR imaging.

PURPOSE: To compare magnetic resonance (MR) imaging features of multiple sclerosis (MS) lesions after the administration of a gadolinium-based contrast agent and ultrasmall superparamagnetic iron oxide (USPIO) particles among the clinical phenotypes of MS and over time. MATERIALS AND METHODS: This study was approved by the local ethics committee, and written informed consent was obtained from all patients. Twenty-four patients with MS (10 with relapsing and 14 with progressive forms) underwent clinical and gadolinium- and USPIO-enhanced MR examinations at baseline and 6-month follow-up. The number of lesions that enhanced with gadolinium alone, USPIO alone, or both was compared with the Pearson χ2 or Fisher exact test, and lesion sizes were compared with the Wilcoxon Mann-Whitney U test. At 6-month follow-up, the lesion signal intensity on precontrast T1-weighted images and the enhancement after repeat injection of the contrast agent were compared with the baseline postcontrast imaging features by using the McNemar test. RESULTS: Fifty-six lesions were considered active owing to contrast enhancement at baseline; 37 lesions (66%) in 10 patients enhanced with gadolinium. The use of USPIO helped detect 19 additional lesions (34%), and two additional patients were classified as having active disease. Thus, the use of both agents enabled detection of 51% (19 of 37 lesions) more lesions than with gadolinium alone. Enhanced lesions were more frequently observed in the relapsing compared with the progressive forms of MS (P<.0001). USPIO enhancement, in the form of ringlike patterns, could also be observed on T1-weighted images in patients with progressive MS, enabling the detection of five lesions in addition to the five detected with gadolinium in this phenotype. Lesions that enhanced with both contrast agents at baseline were larger (mean size, 6.5 mm±3.8; P=.001) and were more likely to persistently enhance at 6-month follow-up (seven of 27 lesions, P<.0001) compared with those that enhanced only with gadolinium (mean size, 4.9 mm±2.2; one of nine lesions) or USPIO (mean size, 3.5 mm±1.5; 0 of 17 lesions). CONCLUSION: The combination of gadolinium and USPIO in patients with MS can help identify additional active lesions compared with the current standard, the gadolinium-only approach, even in progressive forms of MS. Lesions that enhance with both agents may exhibit a more aggressive evolution than those that enhance with only one contrast agent.

Assessment and correction of B1-induced errors in magnetization transfer ratio measurements.

The magnetization transfer ratio (MTR) is strongly related to the field strength (B(1)) of the saturation pulse. B(1) variations therefore can result in significant MTR variations and can affect histogram analysis, particularly if data from a large volume of interest are included. A multicenter study was performed to determine the typical range of B(1) errors and the corresponding MTR variations in brain tissue of healthy volunteers. Seven subjects were included at each center resulting in a total cohort of 28 subjects. Additionally, numerical simulations were done to study this relationship more generally for pulsed saturation. It could be demonstrated, both theoretically and empirically, that for typical B(1) errors there is a linear relationship between B(1) error and the corresponding MTR change. In addition, for proton density-weighted sequences, this relationship seems to be largely independent of the underlying relaxation properties. Mean B(1) errors in the entire brain were typically in the range between -3% and -7%. Due to different coil characteristics, significant MTR differences between different scanners and sites were observed. Using a simple correction scheme that is based on a linear regression analysis between MTR and B(1) data it was possible to reduce the intersubject variation by approximately 50%. Furthermore, interscanner variation could be reduced such that no significant differences between scanners could be detected. The correction scheme may be useful when investigating MTR as an outcome measure in single or multicenter studies.

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.

OBJECTIVE: To evaluate the cost effectiveness of four disease modifying treatments (interferon betas and glatiramer acetate) for relapsing remitting and secondary progressive multiple sclerosis in the United Kingdom. DESIGN: Modelling cost effectiveness. SETTING: UK NHS. PARTICIPANTS: Patients with relapsing remitting multiple sclerosis and secondary progressive multiple sclerosis. MAIN OUTCOME MEASURES: Cost per quality adjusted life year gained. RESULTS: The base case cost per quality adjusted life year gained by using any of the four treatments ranged from pound 42,000 (66,469 dollars; 61,630 euro) to pound 98,000 based on efficacy information in the public domain. Uncertainty analysis suggests that the probability of any of these treatments having a cost effectiveness better than pound 20,000 at 20 years is below 20%. The key determinants of cost effectiveness were the time horizon, the progression of patients after stopping treatment, differential discount rates, and the price of the treatments. CONCLUSIONS: Cost effectiveness varied markedly between the interventions. Uncertainty around point estimates was substantial. This uncertainty could be reduced by conducting research on the true magnitude of the effect of these drugs, the progression of patients after stopping treatment, the costs of care, and the quality of life of the patients. Price was the key modifiable determinant of the cost effectiveness of these treatments.